Nav: Home

Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo

July 02, 2016

BARCELONA-LUGANO, July 2, 2016 - A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data (1) presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralize interleukin-1 alpha (IL-1α), one of the most potent inflammatory substances manufactured by the body or tumour cells.

"IL-1α in tumours promotes angiogenesis, helping to provide crucial blood supply for tumour growth, and it can also send the body's metabolism out of control, causing it to burn muscle and lose weight," said lead investigator Dr Tamas Hickish. At the same time, IL-1α effects on the brain can cause the fatigue, anxiety and anorexia associated with advanced cancer.

The study enrolled 309 patients with metastatic colorectal cancer whose disease had not responded to standard chemotherapy with oxaliplatin and irinotecan and who showed a high degree of symptoms, functional impairment, weight loss or elevated systemic inflammation.

In addition to trialing the new agent, researchers also implemented new criteria for objective response based on control of symptoms, which were developed in collaboration with the European Medicines Agency' Scientific Advice Working Group. These criteria were applied in conjunction with dual-energy X-ray absorptiometry and EORTC-QLQC30 to assess disease control.

Patients were randomized them in a 2:1 ratio to MABp1 with best supportive care, or placebo and the same.

Treatment with MABp1 was associated with a significant 76% relative increase in clinical response rate. Patients who showed a clinical response lived almost three times as long as those who did not respond (11.5 months vs. 4.2 months).

Researchers also found that measures of improved health status correlated with improvement in almost all other self-reported and laboratory-based measures of health, including with improved control of tumor-related white blood cell activity and reduced systemic inflammation.

There were also one-quarter fewer serious adverse events in the treatment arm of the study compared to placebo.

"These data suggest Xilonix is very well tolerated, and has the potential to meet the real and urgent need for more effective, less toxic therapies for patients with advanced colorectal cancer," Dr Hickish said.

"This study also provides the first evidence that health status can actually be used to measure efficacy of anti-tumour therapy in advanced, refractory colorectal cancer, and that clinical responses based on health status can be a predictor of overall survival benefit."
-end-
Notes to Editors

References

1 Abstract O-027 - 'A pivotal phase 3 Trial of MABp1 in advanced colorectal cancer' will be presented by Dr. Tamas Hickish during Session XIX: Colorectal Cancer, on Saturday, 2 July 2016, 11:15 AM (CEST).

Disclaimer

Information contained in this press release was provided by the abstracts authors and reflects the content of the studies. It does not necessarily express ESMO's point of view.

About the ESMO World Congress on Gastrointestinal Cancer

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. It has been endorsed by leading professional societies and organizations.

The Congress is developed and managed by Imedex®, LLC.

About the European Society for Medical Oncology

ESMO is the leading professional organisation for medical oncology. Comprising more than 13,000 oncology professionals from over 130 countries, we are the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

Founded in 1975, ESMO has European roots and a global reach: we welcome oncology professionals from around the world. We are a home for all oncology stakeholders, connecting professionals with diverse expertise and experience. Our educational and information resources support an integrated, multi-professional approach to cancer treatment. We seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.

http://www.esmo.org

O-027

A pivotal phase 3 trial of MABp1 in advanced colorectal cancer

Hickish Tamas1, André Thierry2, Wyrwicz Lucjan3, Saunders Mark4, Sarosiek Tomasz5, Nemecek Radim6, Kocsis Judit7, Stecher Mike8, de Gramont Aimery9

1Oncology Department, Royal Bournemouth Hospital NHS Foundation Trust, Bournemouth, United Kingdom, 2Saint Antoine Hospital, Paris, France, 3M Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland, 4Christie Hospital NHS Foundation Trust, Manchester, United Kingdom, 5Magodent, Warsaw, Poland, 6Masaryk Memorial Cancer Institute, Brno, Czech Republic, 7University of Debrecen, Debrecen, Hungary, 8XBiotech USA, Inc., Austin, Texas, 9Oncology Department, Institut Hospitalier Franco-Britannique, Levallois-Perret, France

Introduction: The incidence of colorectal cancer (CRC) is associated with economic development and is the second leading cause of cancer in the industrialized world. At least half of patients diagnosed will progress and succumb to the disease. Consequently, a substantial and growing unmet need exists for a therapy to treat patients with advanced CRC. We evaluated a novel anti-IL-1 alpha antibody therapy in patients with advanced disease and multiple symptoms known to inversely correlate with overall survival. OR criteria were developed in collaboration with EMA's Scientific Advice Working Group to assess anti-tumor benefit of therapy based on control of these symptoms.

Methods: 309 patients were randomized 2:1 to receive MABp1 plus best supportive care (BSC) versus placebo plus BSC. Patients had metastatic colorectal cancer refractory to standard chemotherapy including oxaliplatin and irinotecan. Inclusion criteria also required a constellation of symptoms/functional impairment (ie. pain, fatigue, anorexia, ECOG 1 or

2), weight loss or elevated systemic inflammation.

Objective response criteria used dual-energy X-ray absorptiometry and EORTC-QLQC30 to assess disease control. Secondary endpoints were pharmacodynamics measures also known to correlate with survival. Data was also reported on incidence of Serious Adverse Events (SAEs) and disease progression. Patients were prohibited from receiving any agents that could affect the outcome, including chemotherapy or steroids.

Results: Primary endpoint analysis was performed on 102 placebo and 207 MABp1 patients using a non-parametric statistical test. A 33% treatment response compared to versus 19% for placebo was significant (p=0.0045). Secondary endpoints were also significant, with improved control of paraneoplastic thrombocytosis and reduced systemic inflammation (IL-6) in treated patients versus placebo (p=0.003 and p=0.004 respectively). Safety and tolerability was excellent as evidenced by a 26% relative risk reduction in the number of SAEs in the treatment arm compared to placebo (p=0.062).

Conclusion: A novel symptom-based OR a criterion was used successfully to assess efficacy of a new anti-cancer agent. These findings provide unequivocal evidence that anti-IL-1alpha monotherapy can serve as a new treatment for advanced mCRC. [NCT02138422]

European Society for Medical Oncology

Related Health Articles:

Public health guidelines aim to lower health risks of cannabis use
Canada's Lower-Risk Cannabis Use Guidelines, released today with the endorsement of key medical and public health organizations, provide 10 science-based recommendations to enable cannabis users to reduce their health risks.
Generous health insurance plans encourage overtreatment, but may not improve health
Offering comprehensive health insurance plans with low deductibles and co-pay in exchange for higher annual premiums seems like a good value for the risk averse, and a profitable product for insurance companies.
The Lancet Planetary Health: Food, climate, greenhouse gas emissions and health
Increasing temperatures, water scarcity, availability of agricultural land, biodiversity loss and climate change threaten to reverse health gains seen over the last century.
With health insurance at risk, community health centers face cut-backs
Repeal of key provisions of the Affordable Care Act, combined with a failure to renew critical funding streams, would result in catastrophic funding losses for community health centers-forcing these safety net providers to cut back on services, lay off staff or shut down clinical sites, according to a report published today.
Study clusters health behavior groups to broaden public health interventions
A new study led by a University of Kansas researcher has used national health statistics and identified how to cluster seven health behavior groups based on smoking status, alcohol use, physical activity, physician visits and flu vaccination are associated with mortality.
Tailored preventive oral health intervention improves dental health among elderly
A tailored preventive oral health intervention significantly improved the cleanliness of teeth and dentures among elderly home care clients.
Study finds that people are attracted to outward signs of health, not actual health
Findings published in the journal Behavioral Ecology reveal that skin with yellow and red pigments is perceived as more attractive in Caucasian males, but this skin coloring does not necessarily signal actual good health.
In the January Health Affairs: Brazil's primary health care expansion
The January issue of Health Affairs includes a study that explores a much-discussed issue in global health: the role of governance in improving health, which is widely recognized as necessary but is difficult to tie to actual outcomes.
University of Rochester and West Health Collaborate on d.health Summit 2017
In collaboration with West Health, the University of Rochester is hosting the third annual d.health Summit, a forum for health care and technology leaders, entrepreneurs, senior care advocates and policymakers to exchange ideas, create new partnerships, and foster disruptive technological and process innovations to improve the lives of the nation's aging population.
Study links health literacy to higher levels of health insurance coverage
The federal Affordable Care Act is intended to make it easier for individuals to buy health insurance, but are the uninsured equipped to navigate the choices faced in the insurance marketplace?

Related Health Reading:

How Not to Die: Discover the Foods Scientifically Proven to Prevent and Reverse Disease
by Michael Greger M.D. (Author), Gene Stone (Author)

Physical Examination and Health Assessment
by Carolyn Jarvis PhD APN CNP (Author)

Psychiatric Mental Health Nursing: Concepts of Care in Evidence-Based Practice
by Mary C. Townsend DSN PMHCNS-BC (Author), Karyn I. Morgan RN MSN APRN CNS (Author)

Essentials of Psychiatric Mental Health Nursing: Concepts of Care in Evidence-Based Practice
by Mary C. Townsend DSN PMHCNS-BC (Author), Karyn I. Morgan RN MSN APRN CNS (Author)

Pocket Companion for Physical Examination and Health Assessment
by Carolyn Jarvis PhD APN CNP (Author)

Mayo Clinic Family Health Book
by Scott C. Litin M.D. (Editor)

Medical Terminology for Health Professions, Spiral bound Version
by Ann Ehrlich (Author), Carol L. Schroeder (Author), Laura Ehrlich (Author), Katrina A. Schroeder (Author)

Laboratory Manual for Physical Examination & Health Assessment
by Carolyn Jarvis PhD APN CNP (Author)

Maternity and Women's Health Care (Maternity & Women's Health Care)
by Deitra Leonard Lowdermilk RNC PhD FAAN (Author), Shannon E. Perry RN PhD FAAN (Author), Mary Catherine Cashion RN BC MSN (Author), Kathryn Rhodes Alden EdD MSN RN IBCLC (Author)

Varcarolis' Foundations of Psychiatric-Mental Health Nursing: A Clinical Approach
by Margaret Jordan Halter PhD APRN (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Circular
We're told if the economy is growing, and if we keep producing, that's a good thing. But at what cost? This hour, TED speakers explore circular systems that regenerate and re-use what we already have. Guests include economist Kate Raworth, environmental activist Tristram Stuart, landscape architect Kate Orff, entrepreneur David Katz, and graphic designer Jessi Arrington.
Now Playing: Science for the People

#504 The Art of Logic
How can mathematics help us have better arguments? This week we spend the hour with "The Art of Logic in an Illogical World" author, mathematician Eugenia Cheng, as she makes her case that the logic of mathematics can combine with emotional resonance to allow us to have better debates and arguments. Along the way we learn a lot about rigorous logic using arguments you're probably having every day, while also learning a lot about our own underlying beliefs and assumptions.